Glenmark’s Novel Molecule For Neuropathic Pain, Osteoarthritis To Enter Phase I Trials

MUMBAI - Indian drug maker Glenmark Pharmaceuticals' lead molecule for neuropathic pain, osteoarthritis and other inflammatory pain will enter Phase I trials shortly, the company announced, after filing for Phase I approval with European regulatory authorities

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip